Human Genome Variation, published by SpringerNature, is an esteemed open access journal dedicated to the field of genetic research and exploration. Since its inception in 2014, the journal has been at the forefront of advancing our understanding of human genome diversity and its implications in health and disease. With an E-ISSN of 2054-345X, it features a diverse array of studies that encompass biochemistry, genetics, and molecular biology, making it an invaluable resource for researchers and professionals alike. The journal holds a Q3 ranking in both biochemistry and genetics, and a Q4 ranking in molecular biology, highlighting its growing influence within these disciplines. As the landscape of genomics continues to evolve, Human Genome Variation serves as a platform for the dissemination of high-quality research, fostering collaboration and innovation within the scientific community. Researchers and academics are invited to contribute to this pivotal journal, which not only provides open access to its content since 2014 but also aims to bridge the gap between basic research and clinical applications in genetics.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.

Frontiers in Genetics is a premier academic journal dedicated to advancing the field of genetics through high-quality, peer-reviewed research. Published by FRONTIERS MEDIA SA in Switzerland since 2010, this Open Access journal provides a platform for researchers and practitioners to disseminate innovative findings across various subfields, including clinical genetics and molecular medicine. With a notable emphasis on interdisciplinary approaches, the journal holds a strong position in the academic landscape, achieving Q2 rankings in key categories such as Genetics and Molecular Medicine in 2023. Not only does Frontiers in Genetics contribute to the scholarly dialogue by publishing impactful studies, but it also promotes accessibility to vital research, ensuring that knowledge is available to a global audience. This journal is a vital resource for researchers, professionals, and students looking to stay at the forefront of genetic discoveries and their applications, reflective of its engagement with contemporary challenges in genetics and healthcare.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

Lifestyle Genomics is a premier open-access journal published by KARGER, based in Switzerland, that bridges the crucial intersection of Food Science, Genetics, and Medicine. Launched in 2008, it aims to disseminate cutting-edge research that explores the intricate relationship between lifestyle factors and genomic influences on health and wellbeing. With an impressive 2023 impact factor reflected in its ranking in the second quartile of Food Science and medicine fields, as well as a noteworthy position in the third quartile for Genetics, the journal is recognized as an influential platform for engaging insights and innovations. The journal is dedicated to facilitating the exchange of knowledge among researchers, healthcare professionals, and students, fostering collaboration and advancing our understanding of personalized medicine. Operating under an open-access model, Lifestyle Genomics ensures that its research is accessible to a global audience, empowering the scientific community to contribute to transformative discoveries that enhance human health.

Genetics Research, published by HINDAWI LTD, is a distinguished open access journal that has been at the forefront of genetic studies since its inception in 1960. With the transition to open access in 2019, this journal has expanded its accessibility, fostering knowledge dissemination across the global scientific community. Operating out of the United Kingdom, it provides a platform for innovative research in the fields of genetics and molecular biology, encompassing a broad range of topics that are highly relevant to medical sciences. As of 2023, it holds a Q4 classification in Genetics and a Q3 classification in miscellaneous Medicine, reflecting its ongoing commitment to scholarly excellence amidst shifting academic landscapes. While the journal's H-index remains unlisted, its indexed ranking within Scopus, with a rank of #325/328 in the Genetics category highlights the challenges ligated to its niche audience. Nevertheless, it serves as a crucial resource for researchers, professionals, and students eager to contribute to and stay informed on the latest genetic research trends and breakthroughs.

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

Pharmakopsychiatry is a distinguished journal published by Georg Thieme Verlag KG that has been at the forefront of research since its inception in 1984. This peer-reviewed journal, with an ISSN of 0176-3679 and E-ISSN of 1439-0795, occupies a pivotal role in the field of medicine, focusing on the intricate intersections of pharmacology, psychiatry, and mental health. Its robust academic standing is demonstrated by its Q2 quartile rankings across multiple categories, including Medicine (miscellaneous) and Psychiatry and Mental Health, showcasing its significant influence with Scopus ranks placing it in the 80th percentile for Psychiatry and Mental Health. Pharmakopsychiatry aims to disseminate cutting-edge research that advances our understanding of pharmacological treatments in psychiatric practice, catering to a diverse audience of researchers, clinicians, and students. With an unwavering commitment to high-quality scholarship and its strategic location in Germany, this journal is an essential resource for those seeking to stay abreast of emerging trends and methodologies in the field.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.